Jump to top menu Jump to main menu Jump to content

J.L. Boormans, MD PhD

Associate professor of Urology

  • Department
  • Urology
  • Focus area
  • Urology
Contact   External Profile



I am Urologist, senior staff member and associate professor at the Erasmus MC Cancer Institute.

My research focus is urothelial cancer. I am involved in a variety of ongoing clinical and translational studies. I supervise 4 PhD students and 1 PostDoc in the field of clinical and translational research in GU cancers.

Field(s) of expertise

My expertise is pelvic and retroperitoneal malignancies. My research focus is urothelial cancer. I perform both robotic and open surgery.

I am currently involved in a variety of ongoing translational clinical studies in urothelial cancer. I am a board member of the Dutch Uro Oncology Study Group (www.stichtingduos.nl) which is a collaborative network of 25 hospitals in the Netherlands and board member of the Dutch Bladder Cancer Infrastructure.

Education and career

I recieved my medical degree at the University of Utrecht and obtained the US medical licensing step I and II in 2001. I specialized in Urology (2004 - 2009). After obtaining my PhD in 2011 I joined the staf of urology at Erasmus MC.

I continued my career at the Erasmus MC Cancer Institute, formerly known as the Daniel den Hoed Cancer Center. In 2019, I was appointed an associate professorship in oncological urology.

Teaching activities

On a yearly basis I give lectures to medical students, residents-in-training and nursing staff.

Other positions

  • Board member of DUOS
  • Board member of Erasmus MC Cancer Institute
  • Board member of ProBCi

Scholarships, grants, and awards


(from – to)

Funding source and project code

Own share of grant (€)

Total grant (€)

Project title

Role of PI*


Mrace grant, 103824



Identification of muscle-invasive bladder cancer patients who will not benefit from neoadjuvant chemotherapy using circulating tumor cells

Principal investigator


KWF, 10319



REduce BlAdder CAncer REcurrences after Nephro-Ureterectomy

Principal investigator





The clonal relation of upper tract urothelial carcinoma and paired urothelial carcinoma of the bladder

Principal investigator


ERA-NET, JTC-2017-8349



MOLecular ChARacterization of Upper Tract Urothelial Carcinoma

Principal investigator, leader of the consortium


ZonMW, 80-84300-98-18572



Comparative effectiveness of bladder sparing treatment versus radical surgery






Pathology revision of metastatic lesions of urothelial carcinoma in addition to WGS

Principal investigator

2020 - 2023

KWF, 12432



The accuracy of detecting residual disease following neo-adjuvant chemotherapy in patients with

muscle-invasive bladder cancer


My Groups

My research focusses on risk stratification and precision medicine of urothelial carcinoma.

I am leading a multicentre study (CirGuidance study) on circulating tumour cells to guide neoadjuvant chemotherapy in bladder cancer patients. I am supervising a PhD student who is developing gene expression profiles of this patient cohort (N=320) together with a diagnostic company in order to improve risk stratification of bladder cancer patients. I am also supervising a PhD student as part of another multicentre study on the efficacy of a preoperative intravesical instillation before radical nephro-ureterectomy in patients with upper tract urothelial carcinoma (REBACARE study), of which I am the lead investigator.

Furthermore, I am leading a European consortium for the molecular characterization of upper tract urothelial carcinoma (MOLCARUTUC consortium), as well as national collaboration on whole genome and transcriptome sequencing data of 100+ urothelial carcinoma metastases together with Hartwig Medical Foundation. In collaboration with the department of Medical Oncology, I am co-supervising a PhD student who runs a biomarker discover study to predict response to pembrolizumab (RESPONDER study).

Lastly, I am co-PI of the Pre-Prevencys study (granted by KWF) to conduct a prospective trial on clinical response prediction to neoadjuvant chemotherapy in patients undergoing radical cystectomy.